Reunion is committed to developing innovative therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, a proprietary, novel, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, is being developed as a potential treatment for postpartum depression that could provide rapid symptom relief and durable efficacy. RE104 is protected under U.S. Patent No. 11,292,765 issued on April 5, 2022 (priority June 30, 2020), with claims for composition of matter, methods of manufacturing, formulations and methods of use for a genus of hemiester tryptamines, including RE104, which could provide protection out to June 30, 2041. Reunion is also developing the RE200 series, which includes preclinical compounds with enhanced receptor selectivity to address additional therapeutic applications.
Company profile
Ticker
REUN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Field Trip Health Ltd.
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12G
Securities registration termination
18 Aug 23
6-K
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
1 Aug 23
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
1 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Aug 23
25-NSE
Exchange delisting
1 Aug 23
6-K
Current report (foreign)
19 Jul 23
6-K
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement
13 Jul 23
6-K
Current report (foreign)
7 Jul 23
40-F
2023 FY
Annual report (Canada)
29 Jun 23
Financial summary
Quarter (USD) | Mar 23 | Mar 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
58.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 21 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.91 bn |
Total shares | 6.86 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MPM Oncology Impact Management | 5.13 mm | $3.54 mm |
Beryl Capital Management | 687.63 k | $777.02 mm |
Oasis Management | 467.44 k | $511.96 mm |
AdvisorShares Investments | 271.33 k | $306.60 mm |
Crystalline Management | 151.25 k | $170.92 mm |
One + One Wealth Management | 76.00 k | $85.88 mm |
Cidel Asset Management | 20.00 k | $21.92 mm |
KG&L Capital Management,LLC | 20.00 k | $22.60 mm |
Virtu Financial | 17.59 k | $20.00 k |
CIBC World Markets | 10.26 k | $11.00 k |